Middle East and Africa Antibiotics Market Report

To learn more about this report, Download Free Sample Report

Middle East and Africa Antibiotics Market Size

The Middle East and Africa antibiotics market size was valued at USD 2.76 billion in 2025 and is anticipated to reach USD 2.93 billion in 2026 from USD 4.74 billion by 2034, growing at a CAGR of 6.2% during the forecast period from 2026 to 2034.

The market for antibiotics in MEA is majorly driven by implementing regulations to prevent the spread of animal diseases and the growing demand for animal-derived products. Also, the proliferation of contagious diseases and favorable supportive government initiatives for developing antibiotics in the region is most likely to accelerate the market growth. In addition, the rising prevalence of drug-resistant bacteria has prompted many manufacturers and R&D institutions to develop innovative antimicrobial variations that have been proved to be effective against both new and old bacterial strains. Over the projected period, the market is likely to be driven by pharmaceutical firms' increasing efforts to discover innovative treatments to treat infectious illnesses and a rising number of research and development activities.

Furthermore, an increase in antibiotic resistance infections resulting from antibiotic abuse or overuse is predicted to alter prescription trends toward new antibacterial treatments. Another factor boosting the market in the MEA region is the lifestyle of smoking, which leads to diseases such as tuberculosis and other respiratory infections that need antibiotic infusions. The spread of dangerous and undesirable bacterial strains inside or on the human body is called bacterial infection. These bacteria can infect any part of the human body, causing severe health problems; therefore, it influences the demand for antibiotics.

Further, supporting government legislation such as the GAIN Act and the REVAMP Act is likely to speed up the approval process. The introduction of new antimicrobial medicines is projected to drive market growth throughout the projection period. Pharmaceutical firms are working on developing novel medicines to lower the cost of medication development. The rise in the number of Collaborations for antibiotic development in the region is likely to create many antibiotic medicines in the near future. 

Despite significant regional demand, the high cost of producing antibiotics is anticipated to pose a challenge to the regional antibiotics market's development throughout the forecast period. However, the limited number of novel antibiotics, developing antimicrobial and antibiotic resistance, and improving good husbandry and hygiene practices are likely to impede the market's growth. 

Impact of COVID-19 on the MEA Antibiotics Market

The epidemic of COVID-19 began at a meat market in Wuhan (China), and it has had a detrimental impact on the consumption of animal-based foods; this can be related to the emergence of numerous livestock-borne illnesses such as swine flu, Zika virus, Hantavirus, and the current avian flu, among others. Additionally, trade obstacles in some areas and the use of alternative sources, such as plant-based components, are likely to limit market expansion. During the pandemic period, antibiotics stewardship initiatives in hospitals and communities were interrupted, and antibiotics were prescribed for COVID patients misdiagnosed with bacterial bronchitis, over-prescription in telehealth consultations, and easy access to medications from internet pharmacies were all linked to AMR. This is likely to have an adverse impact on consumer attitudes about items derived from animals. COVID-19 is expected to have a limited effect on the market for antimicrobials and antibiotics for animals. Limited access to present and future clients has hampered market participants' ability to sell new antimicrobial susceptibility testing systems and install previously sold systems, resulting in reduced antimicrobial production growth. 

REGIONAL ANALYSIS

Geographically, the MEA antibiotics market is growing at a CAGR of 6.2% during the forecast period. The market growth in the region is primarily attributed to the prevalence rate of infectious diseases, increase in regional animal population and rise in government initiatives to develop novel therapies to treat drug-resistant infections and the presence of key market players. Research institutes and medical device manufacturers have been focussing on introducing antibiotics with safety and effectiveness, which is expected to uplift the market growth. The major growth contributors in the region are South Africa, Saudi Arabia, and the developing countries UAE, Egypt, Israel. During the forecast period, Saudi Arabia and the United Arab Emirates is are expected to account significant share in Middle East Africa. Developing healthcare infrastructure and increasing healthcare expenditure are most likely to propel the antibiotics market in the country. Also, the advancement of medicine has resulted in the availability of a wide range of antibiotics and increased specialization in the pharmaceutical industry, resulting in market expansion.

KEY MARKET PLAYERS

Johnson and Johnson, GlaxoSmithKline, Pfizer PLC, Bayer AG, Novartis AG, Abbott Inc., Merck & Co. Inc., Sanofi SA, and F. Hoffmann-La Roche AG are a few of the dominating companies operating in the MEA antibiotics market.

MARKET SEGMENTATION

This research report on the Middle East & Africa antibiotics market has been segmented and sub-segmented based on the following categories.

By Action Mechanism

• Cell Wall Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Rna Synthesis Inhibitors
• Mycolic Acid Synthesis Inhibitors
• Folic Acid Synthesis Inhibitors

By Drug Class

• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamides
• Others

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA